SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ____________________  FORM
10-Q ____________________  [X] QUARTERLY REPORT UNDER SECTION 13 OR
15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934  For the quarterly period ended September
30, 2008  [  ] TRANSITION REPORT UNDER SECTION
13 OR 15 ( d ) OF THE EXCHANGE ACT  For the transition period from
____________ to____________  Commission File No. 000-49655   LIPIDVIRO TECH, INC. (Exact name of Registrant as specified in
its charter)  Nevada
87-0678927(State or Other Jurisdiction of
(I.R.S. Employer Identification No.)incorporation or organization)  1338 S. Foothill Drive, #126 Salt Lake City, Utah  84108 (Address of Principal Executive Offices)  (801) 583-9900 (Registrants telephone number, including
area code)  N/A (Former name, former address and former
fiscal year, if changed since last report)  Indicate by check mark whether the
Registrant has (1) filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 (the Exchange Act) during the preceding
12 months (or for such shorter period that the Registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X] No [  ]  Indicate by check mark whether the
Registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company.  See definition of large
accelerated filer, accelerated filer and smaller reporting company in Rule
12b-2 of the Exchange Act.  (Check one):  Large accelerated filer   [  ]
                                                                     Accelerated
filer [  ]  Non-accelerated filer     [  ]
                                                                     Smaller
reporting company  [X] (Do not check if a smaller reporting company)  Indicate by check mark whether the
Registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes [ X ] No [  ]  1     APPLICABLE ONLY TO ISSUERS INVOLVED IN
BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE
YEARS  Indicate by check mark whether the
registrant has filed all documents and reports required to be filed by Sections
12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the
distribution of securities under a plan confirmed by a court.  Not applicable.  APPLICABLE ONLY TO CORPORATE ISSUERS  Indicate the number of shares outstanding of each of the
Registrants classes of common stock, as of the latest practicable date:
 October 31, 2008 - 1,305,344 shares of common stock.  PART I   Item 1.  Financial Statements  The Financial Statements of the Registrant
required to be filed with this 10-Q Quarterly Report were prepared by management
and commence below, together with related notes. In the opinion of management,
the Financial Statements fairly present the financial condition of the
Registrant.      2           LIPIDVIRO TECH, INC. (A Development Stage Company) SEPTEMBER 30, 2008 CONDENSED FINANCIAL
STATEMENTS  3       TABLE OF CONTENTS  PAGE   Unaudited Condensed Consolidated
Balance Sheets, September
30, 2008 and December 31, 2007 5    Unaudited Condensed Consolidated
Statements of Operations, for the three
months and nine months ended September 30, 2008 and 2007 and for the period from
inception on May 6, 2003
through September 30, 2008 6   Unaudited Condensed Consolidated
Statements of Cash Flows, for the nine
months ended September 30, 2008 and 2007 and for the period from
inception on May 6, 2003
through September 30, 2008 7    Notes
to Unaudited Condensed Consolidated Financial Statements 9 - 12  4


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED BALANCE SHEETS  ASSETS September 30,
2008

December 31, 2007CURRENT ASSETS:




(Consolidated)Cash
$
-

$
46Total
Current Assets

-


46PROPERTY AND EQUIPMENT, net

-


747OTHER ASSETS:Definite-life intangible
assets

-


34,637Goodwill

-


290,317TOTAL
ASSETS
$
-

$
325,747LIABILITIES AND STOCKHOLDERS EQUITY
(DEFICIT)CURRENT LIABILITIES:Accounts
payable
$
38,001

$
275,364Accounts payable
subject to indemnification

178,112


-Related party
loans

39,508


686,124Total
Current Liabilities

255,621


961,488LONG-TERM LIABILITIES:Related party accrued
interest

-


67,562Related party note
payable

-


600,000Total
Liabilities

255,621


1,629,050STOCKHOLDERS EQUITY (DEFICIT):Common Stock, $.001 par value,
150,000,000 shares authorized,
1,305,344 and
1,305,334 shares issued and outstanding, respectively

1,305


1,305Capital in excess of par value

4,852,612


3,787,642Deficit accumulated during the
development stage

(5,109,538)


(5,092,250)Total
Stockholders Equity (Deficit)

(255,621)


(1,303,303)TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
$
-

$
325,747  The accompanying notes are an integral part
of these financial statements.


5


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS  For the Three Months Ended
September 30,

For the Nine Months Ended
September 30,

For the Period From
Inception on May 6, 2003, through September 30,2008

2007

2008

2007

2008REVENUE
$
-

$
-

$
-

$
-

$
-OPERATING EXPENSES:Consulting

-


-


608


306,500


564,269Employee Compensation

-


40,311


13,437


120,932


322,598Professional fees

24,745


5,697


91,846


30,884


348,770Other General and
administrative

-


491


-


38,778


101,223Total
Operating Expenses

24,745


46,499


105,891


497,094


1,336,860OPERATING LOSS

(24,745)


(46,499)


(105,891)


(497,094)


(1,336,860)OTHER EXPENSES:Related party interest
expense

(16,038)


(29,083)


(46,317)


(249,060)


(1,565,099)LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAX
PROVISION

(40,783)


(75,582)


(152,208)


(746,154)


(2,901,959)PROVISION FOR INCOME TAXES

-


-


-


-


-LOSS FROM CONTINUING OPERATIONS

(40,783)


(75,582)


(152,208)


(746,154)


(2,901,959)DISCONTINUED OPERATIONS:Income (loss) from
operations of
discontinued
research business

242,882


(70,339)


134,920


(208,217)


(2,207,579)Income tax expense

-


-


-


-


-INCOME (LOSS) ON DISCONTINUED OPERATIONS

242,882


(70,339)


134,920


(208,217)


(2,207,579)NET INCOME (LOSS)
$
202,099

$
(145,921)

$
(17,288)

$
(954,371)

$
(5,109,538)BASIC AND DILUTED INCOME (LOSS) PER SHAREContinuing operations
$
(0.03)

$
(0.06)

$
(0.12)

$
(0.59)Discontinued operations

0.18


(0.05)


0.11


(0.16)Net income (loss)
$
0.15

$
(0.11)

$
(0.01)

$
(0.75)WEIGHTED AVERAGE SHARES OUTSTANDING

1,305,136


1,289,197


1,303,241


1,276,469  The accompanying notes are an integral part
of these financial statements.


6


LIPIDVIRO TECH,
INC. (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS  For the Nine Months Ended
September 30,

For the Period From Inception On May
6, 2003 through
September 30,2008

2007

2008CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)
$
(17,288)
$
(954,371)
$
(5,109,538)Adjustments to reconcile net income
(loss) to net cash
used by operating
activities:Depreciation

465

551

3,393Expense costs related to
unsuccessful financing
Transaction

-

-

31,900Gain on settlement of
debt

(250,082)

-

(250,082)Imputed interest
expense

-

-

42,377Noncash expenses paid by a
shareholder

-

-

6,900Noncash expenses paid by
issuance of common stock

-

201,967

1,346,919Noncash services paid by
issuance of common stock

90,500

438,597

1,239,726Noncash services paid by
grant of warrants

35,243

153,641

1,460,695Net (increase) decrease in
operating assets:Retainer

-

10,000

-Net increase (decrease) in
operating liabilities:Accounts payable

54,827

24,995

329,186Related party loans -
interest

23,858

24,655

86,532Related party accrued
interest

22,458

22,438

90,020Net Cash
Used by Operating Activities

(40,019)

(77,527)

(721,972)CASH FLOWS FROM INVESTING ACTIVITIES:
Cash of former subsidiary

(25)

-

(25)Payments for property and
equipment

-

-

(3,675)Payments for definite-life intangible
assets

-

(300)

(33,632)Payments for goodwill

-

-

(269,006)Net Cash
Used by Investing Activities

(25)

(300)

(306,338)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from related party
loans

38,518

68,545

670,667Payments on related party loans

-

(4,500)

(8,700)Proceeds from capital
contributions

1,480

15,379

34,133Proceeds from common stock
issuances

-

-

293,700Proceeds from sale of warrants

-

-

38,510Net Cash
Provided by Financing Activities

39,998

79,424

1,028,310  (Continued)


7


LIPIDVIRO TECH, INC. (A Development Stage Company) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS (Continued) For the Nine Months Ended
September 30,

For the Period From Inception On May
6, 2003 through
September 30,2008

2007

2008NET INCREASE (DECREASE) IN CASH

(46)

1,597

-CASH AT BEGINNING OF PERIOD

46

236

-CASH AT END OF PERIOD
$
-
$
1,833
$
-SUPPLEMENTAL DISCLOSURES OF CASH FLOW
INFORMATION:
Cash paid during the period for:Interest
$
-
$
-
$
-Income Taxes
$
-
$
-
$
-SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND
FINANCING ACTIVITIES:Liabilities settled by disposition of
Subsidiary with $25
in cash, $282 in net
property and equipment, $290,317
in goodwill, and $19,074 in
accounts payable at the
time of disposition
$
1,209,297
$
-
$
1,209,297Liabilities settled by transferring
patents of 34,637
$
284,719
$
-
$
284,719Definite-life intangible asset fees
accrued in accounts
payable
$
-
$
-
$
1,005Deferred financing costs paid
 through issuance of
common stock
$
-
$
-
$
31,900Common stock repurchased through
issuance of
$600,000 note payable and
$1 paid by a shareholder
$
-
$
-
$
600,001Common stock issued to purchase
minority interest
$
-
$
-
$
21,311   The accompanying notes are an integral part
of these financial statements.


8


LIPIDVIRO TECH, INC. (A
Development Stage Company) NOTES TO
THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 1  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  The accompanying financial statements have been prepared
by the Company in accordance with Article 8 of U.S. Securities and Exchange
Commission Regulation S-X.  In the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to present fairly
the financial position, results of operations and cash flows at September 30,
2008 and 2007 and for the periods then ended have been made.  Certain
information and footnote disclosures normally included in financial statements
prepared in accordance with U.S. generally accepted accounting principles have
been condensed or omitted.  It is suggested that these condensed financial
statements be read in conjunction with the financial statements and notes
thereto included in the Company's December 31, 2007 audited financial
statements.  The results of operations for the periods ended September 30,
2008 and 2007 are not necessarily indicative of the operating results for the
full year.  NOTE 2  GOING CONCERN  The Companys financial statements have been presented on
the basis that it is a going concern, which contemplates the realization of
assets and the satisfaction of liabilities in the normal course of business.
 At September 30, 2008, the Company had incurred losses since inception,
had no revenue-generating activities, had negative cash flows from operating
activities, and had current liabilities in excess of current assets.  These
factors create an uncertainty about the Companys ability to continue as a going
concern.  In this regard, management is proposing to raise any necessary
additional funds not provided by operations through loans or through additional
sales of common stock.  There is no assurance that the Company will be
successful in raising this additional capital or in achieving profitable
operations.  The financial statements do not include any adjustments that
might be necessary if the Company is unable to continue as a going concern.  NOTE 3  SALE OF RESEARCH ASSETS  On January 3, 2008, for consideration of $100 the Company
granted a 60-day option to AcquiSci, Inc. (a New Jersey corporation) to purchase
the Companys research subject to the terms of a Purchase Agreement.  The
Purchase Agreement called for AcquiSci, Inc., its shareholders, and their
related entities to release the Company from debts totaling $284,719 in exchange
for all of the Companys research including the Companys pending patent
applications.  In January 2008, AcquiSci, Inc. exercised its option and the
Purchase Agreement closed on September 29, 2008.  This transaction effected
a discontinuation of the Companys research business [See Note 4].  NOTE 4  DISCONTINUED OPERATIONS  On September 29, 2008, the Company discontinued its
research business by selling its research assets [See Note 3].  The
Company decided to discontinue its research business because it has not
generated any revenues, financing has not been available for clinical trials,
and the board of directors wants to prepare the Company to pursue other
opportunities.  Operations of the research business have been reclassified
in the statements of operations for all periods presented.  The following
is a summary of the results of operations of the discontinued research
business.  For the Nine Months Ended September
30,

For the Period From Inception on May
6, 2003 Through September 30, 20082008

2007Revenue
$
-

$
-

$
-General and administrative

(2,130)


(3,237)


(47,246)Research and development

(113,078)


(204,890)


(2,410,307)Gain on settlement of debt

250,082


-


250,082Interest income

-


-


23Foreign currency transaction gain (loss)

46


(90)


(131)Income taxes

-


-


-Net income (loss)
$
134,920

$
(208,217)

$
(2,207,579)


9


LIPIDVIRO TECH, INC. (A
Development Stage Company) NOTES TO
THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 5  RELATED PARTY TRANSACTIONS  Disposition of Subsidiary  On September 30, 2008, the
Company transferred 100% of its ownership of Subsidiary to Benedente Holdings,
LLC (Benedente) to settle debts totaling $1,209,297 [See below] in
accordance with an Option Agreement dated December 17, 2007 and amended January
23, 2008.  As part of the agreement, Benedente indemnified the Company
against the Companys accounts payable as of March 31, 2008 [See below].
 At the time of the transfer, Subsidiarys assets and liabilities consisted
of $25 in cash, $282 in net property and equipment, $290,317 in goodwill, and
$19,074 in accounts payable.  Due to the related party nature of the
$1,209,297 of debts settled for net assets totaling $271,550, the Company
recorded the gain as a capital contribution.  The financial statements
presented include the operations of Subsidiary from its inception on May 6, 2003
through September 30, 2008 and the balance sheet reflects the disposition of
Subsidiary.  Accounts Payables Subject to Indemnification  As part of
an Option Agreement [See above], Benedente indemnified the Company
against the Companys accounts payable that existed on March 31, 2008.
 Further, Benedente agreed to negotiate settlements of those accounts
payable.  As of September 30, 2008, $178,112 of those accounts payable had
not yet been settled and have been classified in the balance sheet as accounts
payable subject to indemnification because the Company is uncertain whether
Benedente has the ability to pay or otherwise settle these liabilities.  Related Party Loans  During the nine months ended
September 30, 2008, shareholders or entities related to them loaned $38,518 to
the Company.  In April 2008, the Company started accruing interest at 8%
per annum on related party loans that previously bore no interest.  The
Company repaid loans totaling $189,715 through the transfer of research assets
[See Note 3] and the Company repaid loans totaling $519,277 through the
disposition of Subsidiary [See above].  At September 30, 2008, the
Company owed a total of $39,508 to the related parties.  During the nine
months ended September 30, 2008 and 2007, the Company accrued interest expense
on related party loans totaling $23,858 and $24,655, respectively.  Note Payable  The Company repaid the $600,000 note
payable and accrued interest totaling $90,020 through the disposition of
Subsidiary [See above].  During the nine months ended September 30,
2008 and 2007, interest expense on the note payable amounted to $22,458 and
$22,438, respectively.  Capital Contributions  During the nine months ended
September 30, 2008, a shareholder of the Company contributed cash and made
payments on behalf of the Company totaling $1,480.  NOTE 6  COMMON STOCK, OPTIONS, AND WARRANTS  Reverse Stock Split  On September 5, 2008, the Company
effected a 1-for-14 reverse split of the Companys outstanding common stock.
 The financial statements for all periods presented have been restated to
reflect this reverse split.  Warrant Expiration  All of the Companys warrants
expired unexercised on June 30, 2008.  Warrant Vesting  Of the 3,007 warrants unvested at
December 31, 2007, 1,042 Class A warrants and 1,786 Class B warrants vested
during the six months ended June 30, 2008.  The remaining 179 Class B
warrants expired unvested.  Share-Based Payment Disclosures - During the nine months
ended September 30, 2008 and 2007, share-based payments resulted in expenses of
$125,743 and $794,205, respectively.


10


LIPIDVIRO TECH, INC. (A
Development Stage Company) NOTES TO
THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 6  COMMON STOCK, OPTIONS, AND WARRANTS
[Continued]  A summary of warrant activity as of September 30, 2008
and changes during the nine months then ended is presented below:  Warrants

Shares

Weighted-Average Exercise Price

Weighted-Average Remaining Contractual
Term (Years)

Aggregate Intrinsic ValueOutstanding at December 31, 2007

2,039,645

$
14.93Granted

-


-Exercised

-


-Forfeited

-


-Expired

(2,039,645)


14.93Outstanding at September 30, 2008

-

$
-

-

$
-Exercisable at September 30, 2008

-

$
-

-

$
-  A summary of the status of the non-vested shares as of
September 30, 2008 and changes during the nine months then ended is presented
below:  Non-vested Shares

Shares

Weighted-Average Grant-Date
Fair ValueNon-vested at December 31, 2007

4,911

$
18.43Vested

(4,911)


18.43Non-vested at September 30, 2008

-

$
-  As of September 30, 2008, there was no unrecognized
expense related to non-vested share-based payments and there were no non-vested
shares outstanding.  The total fair value of shares vested during the nine
months ended September 30, 2008 was $90,500.  NOTE 7  FOREIGN CURRENCY TRANSACTION  During the nine months ended September 30, 2008, the
Company recorded a foreign currency transaction gain of $46 due to the change in
the exchange rate.  These fees are owed by Subsidiary and were included in
the accounts payable eliminated through the disposition of Subsidiary [See
Note 5].  NOTE 8  INCOME TAXES  At September 30, 2008, the Company has net operating loss
carryovers of approximately $407,600 available to offset future taxable income
and expiring beginning in 2023 through 2028.  Due to a change in control of
the Company in January 2008, the net operating loss carryovers will be subject
to an annual limitation of approximately $19,800.


11


LIPIDVIRO TECH, INC. (A
Development Stage Company) NOTES TO
THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  NOTE 8  INCOME TAXES [Continued]  The income tax provision differs from the amounts that
would be obtained by applying federal and state statutory income tax rates to
loss from continuing operations before income taxes as follows:  For the Nine Months Ended September
30,

For the Period From Inception on May
6, 2003 Through September 30, 20082008

2007Loss before income tax provision
$
(152,208)

$
(746,154)

$
(2,901,959)Expected combined federal and state income tax
rate

20.0%


20.0%


20.0%Expected income tax expense (benefit) at statutory
rates

(30,442)


(149,231)


(580,392)Federal benefit of state taxes

1,142


5,596


21,765Tax effect of:Expired warrant expenses

2,587


23,279


62,100Meals and entertainment

-


22


82Non-deductible interest
expense

8,916


47,944


301,282Change in valuation allowance

17,797


72,390


195,163Net income tax expense (benefit)
$
-

$
-

$
-  The Companys deferred tax assets, deferred tax
liabilities, and valuation allowance are as follows:  September 30, 2008Deferred tax assets:Net operating loss
carryovers
$
78,462Total deferred tax assets
$
78,462Deferred tax liabilities
$
-Total deferred tax liabilities
$
-Total deferred tax assets
$
78,462Total deferred tax liabilities

-Valuation allowance

(78,462)Net deferred tax asset (liability)
$
-  NOTE 9  COMMITMENTS  In February 2007, a vendor obtained a $16,166 default
judgment against Subsidiary for an unpaid invoice.  The judgment provides
for interest at an annual rate of 6.36%.  At September 30, 2008, Subsidiary
owed $17,816 on the judgment and the amount was included in the accounts payable
eliminated through the disposition of Subsidiary [See Note 5].


12


Item 2. Managements Discussion and Analysis of Financial Condition and
Results of Operations.  Forward-looking Statements  Statements made in this Quarterly Report which are not
purely historical are forward-looking statements with respect to the goals, plan
objectives, intentions, expectations, financial condition, results of
operations, future performance and our business, including, without limitation,
(i) our ability to raise capital, and (ii) statements preceded by, followed by
or that include the words may, would, could, should, expects,
projects, anticipates, believes, estimates, plans, intends,
targets or similar expressions.  Forward-looking statements involve inherent risks and
uncertainties, and important factors (many of which are beyond our control) that
could cause actual results to differ materially from those set forth in the
forward-looking statements, including the following, general economic or
industry conditions, nationally and/or in the communities in which we may
conduct business, changes in the interest rate environment, legislation or
regulatory requirements, conditions of the securities markets, our ability to
raise capital, changes in accounting principles, policies or guidelines,
financial or political instability, acts of war or terrorism, other economic,
competitive, governmental, regulatory and technical factors affecting our
current or potential business and related matters.  Accordingly, results actually achieved may differ
materially from expected results in these statements.  Forward-looking
statements speak only as of the date they are made.  We do not undertake,
and specifically disclaim, any obligation to update any forward-looking
statements to reflect events or circumstances occurring after the date of such
statements.  Plan of Operation  Disposition of the Technology.  On September 29, 2008, LipidViro Tech,
Inc., a Utah corporation (LipidViro Utah), which is a wholly-owned subsidiary
of LipidViro Tech, Inc., a Nevada corporation (the Company), completed the
transfer to AcquiSci, Inc., a New Jersey corporation, of certain technology that
comprised substantially all of its assets and, by extension, substantially all
of the Companys assets (the Technology).  The Technology includes 12 patent applications, together
with related documentation, prototypes, know-how, trade secrets and technical
data, all as discussed in detail in the Companys Current Report on Form 8-K
dated September 29, 2008, which was filed with the Securities and Exchange
Commission on October 1, 2008.  In consideration of the Technology,
AcquiSci delivered to LipidViro Utah:  (a) the sum of $1.00;  (b) executed releases of all claims
against the Company and LipidViro Utah by Joseph Latino; Geribald Investments,
LLC; Linda Sharkus; AcquiSci, Inc.; and Acquis Associates;  (c) (i) 616,000 shares of the Companys
common stock; (ii) a Class A Warrant to purchase 560,000 shares of the Companys
common stock at a price of $0.71 per share, exercisable through June 30, 2008;
and (iii) a Class B Warrant to purchase 560,000 shares of the Companys common
stock at a price of $1.43 per share, exercisable through June 30, 2008, all of
which were owned by Mr. Latino and/or Geribald Investments; and  (d) (i) 295,793 shares of the Companys
common stock; and (ii) a Class A Warrant to purchase 70,000 shares of the
Companys common stock at a price of $0.71 per share, exercisable through June
30, 2008, all of which were held by Ms. Sharkus and/or Acquis Associates.  B. Disposition of LipidViro
Utah.  On September 30, 2008, following the
completion of the Technology disposition, the Company executed a Bill of Sale by
which it assigned to Benedente Holdings, LLC, a Wyoming limited liability
company, 9,843,750 shares of common stock of LipidViro Utah (the Shares),
which Shares constituted all of the issued and outstanding shares of LipidViro
Utah common stock.  Benedente is controlled by Steven Keyser, who is a
director of the Company.  For more information regarding the disposition of
technology or the disposition of LipidViro Utah, see our 8-K Current Report
dated September 29, 2008.


13


Our plan of operation for the next 12 months is to: (i)
consider guidelines of industries in which we may have an interest;(ii) adopt a
business plan regarding engaging in the business of any selected industry; and
(iii) to commence such operations through funding and/or the acquisition of a
going concern engaged in any industry selected.  During the next 12 months, our only foreseeable cash
requirements will relate to the payment of our Securities and Exchange
Commission and Exchange Act reporting filing expenses, including associated
legal and accounting fees; costs incident to reviewing or investigating any
potential business venture; and maintaining our good standing as a corporation
in our state of organization.  We anticipate that these funds will be
provided to us in the form of loans from Jenson Services.  There are no
written agreements requiring Jenson Services to provide these cash resources;
and to the extent funds are provided, such funds will bear no interest (though
an interest expense of 10% has been imputed on funds advanced) and will be due
on demand.  As of the date of this Quarterly Report, we have not actively
begun to seek any business or acquisition candidate.  Results of Operations  During the quarters ended September 30, 2008, and 2007,
we had losses from continuing operations of $40,783 and $75,582 and income and
loss from discontinued operations of $242,882 and ($70,339) for a net income and
loss of $202,099 and ($145,921), respectively.  During the nine months
ended September 30, 2008, and 2007, we had losses from continuing operations of
$152,208 and $746,154 and income and loss from discontinued operations of
$134,920 and ($208,217) for a net loss of $17,288 and $954,371,
respectively.  Liquidity  We have no current cash resources.  During the next 12 months, our only
foreseeable cash requirements will relate to the payment of our Securities and
Exchange Commission and Exchange Act reporting filing expenses, including
associated legal and accounting fees; costs incident to reviewing or
investigating any potential business venture; and maintaining our good standing
as a corporation in the State of Nevada.  We do not have any cash reserves
to pay for our administrative expenses for the next 12 months.  In the
event that additional funding is required in order to keep us in good standing,
we may attempt to raise such funding through loans or through additional sales
of our common stock.    Item 3.  Quantitative and
Qualitative Disclosures About Market Risk.  Not required.  Item 4T.  Controls and Procedures.  Evaluation of disclosure controls and procedures  Our management, with the participation of our chief
executive officer and chief financial officer, evaluated the effectiveness of
our disclosure controls and procedures as defined in Rule 13a-15(e) under the
Exchange Act as of the end of the period covered by this Quarterly Report on
Form 10-Q.  In designing and evaluating the disclosure controls and
procedures, our management recognized that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives.  In addition, the design of
disclosure controls and procedures must reflect the fact that there are resource
constraints and that management is required to apply its judgment in evaluating
the benefits of possible controls and procedures relative to their costs.
 The design of any disclosure controls and procedures also is based in part
upon certain assumptions about the likelihood of future events and there can be
no assurance that any design will succeed in achieving its stated goals under
all potential future conditions.  Based on that evaluation, our chief executive officer and
chief financial officer concluded that, as of September 30, 2008, our disclosure
controls and procedures were, subject to the limitations noted above, effective
to provide reasonable assurance that information we are required to disclose in
reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in Securities and
Exchange Commission rules, regulations and forms, and that such information is
accumulated and communicated to our management, including our chief executive
officer and chief financial officer, as appropriate, to allow timely decisions
regarding required disclosure.


14


Changes in internal control
over financial reporting  Our management, with the participation of
the chief executive officer and chief financial officer, has concluded there
were no significant changes in our internal controls over financial reporting
that occurred during our last fiscal quarter that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting.  PART II - OTHER INFORMATION   Item 1. Legal Proceedings.  In February 2007, Friedrich and Dimmock, Inc., a vendor,
obtained a $16,166 default judgment against the Company for an unpaid invoice.
 The judgment provides for interest at an annual rate of 6.36%.  At
September 30, 2008, the Company owed $17,816 on the judgment and the amount was
included in the accounts payable eliminated through the disposition of LipidViro
Utah.  Item 1A.  Risk
Factors.  Not required.   Item 2. Unregistered Sales of Equity Securities and
Use of Proceeds.  None; not applicable.   Item 3. Defaults Upon Senior Securities.  None; not applicable.   Item 4. Submission of Matters to a Vote of Security
Holders.  On April 2, 2008, our Board of Directors and three
individuals who collectively own approximately 55.9% of our issued and
outstanding shares of common stock voted:  · to effect a reverse split of our
issued and outstanding shares of common stock in the ratio of one-for-14, with
appropriate adjustments in our additional paid-in capital and stated capital
accounts and with all fractional shares to be rounded up to the nearest whole
share;  · to adopt, approve and ratify the sale
of the Technology; and  · to transfer all of the Companys
shares of its wholly-owned subsidiary, LipidViro Utah, to Benedente Holdings,
LLC, a Wyoming limited liability company, in consideration of Benedentes
agreement to use its best efforts to negotiate the settlement of the Companys
outstanding liabilities.  On July 18, 2008, we filed with the Securities and
Exchange Commission a Definitive Information Statement with respect to each of
these matters.  These transactions were effective on or about September 5,
2008.   Item 5. Other Information.  None; not applicable.  Item 6. Exhibits.   Exhibit No.                       Identification
of Exhibit  31

32
Certification of Kenneth Hamik Pursuant to Section
302 of the Sarbanes-Oxley Act.

Certification of Kenneth Hamik Pursuant to 18
U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the
Sarbanes-Oxley Act.


15


SIGNATURES  Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized  LIPIDVIRO TECH, INC.  Date:
November 7, 2008

By:
/s/Kenneth P. HamikKenneth P. Hamik, President, Chief Executive
Officer and DirectorDate:
November 7, 2008

By:
/s/Steven KeyserSteven Keyser, Director


16